HR. 1672In Committee
Maintaining Investments in New Innovation Act
Plain-English overview
What this bill does
Requires genetically targeted drugs to have at least 11 years of market approval before they can qualify for the Medicare Drug Price Negotiation Program
Key points
- Require 11 years market approval
- Modify Medicare drug negotiation eligibility
Current status
Where it stands
Status
In Committee
Latest action
2025-02-27 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related context
Topics and policy areas
Select a topic to continue exploring related legislation, members, and committees.
Discovery signals
About these signals
Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.
Impact ScoreOverall observed legislative footprint and accumulated activity.
MomentumHow recently active or changing the bill appears in available data.